Abstract
23-Valent pneumococcal polysaccharide vaccine was previously reported to be ineffective in HIV-infected Ugandan adults. Prolonged follow-up of trial participants confirmed persistent excess of all-cause pneumonia in vaccine recipients [hazard ratio (HR) 1.6; 95% confidence interval (CI) 1.0-2.4], but surprisingly a survival advantage favouring vaccination (HR 0.84; CI 0.7-1.0). An explanation for the improvement in survival in the face of excess morbid events is lacking; a role for vaccine in HIV care in Africa remains unlikely.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
AIDS-Related Opportunistic Infections / complications
-
AIDS-Related Opportunistic Infections / mortality
-
AIDS-Related Opportunistic Infections / prevention & control*
-
Adult
-
Cohort Studies
-
Follow-Up Studies
-
HIV Infections / complications*
-
HIV Infections / mortality
-
Humans
-
Pneumococcal Vaccines*
-
Pneumonia, Viral / complications
-
Pneumonia, Viral / mortality
-
Pneumonia, Viral / prevention & control*
-
Randomized Controlled Trials as Topic
-
Regression Analysis
-
Uganda / epidemiology